Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio
Anchiano Therapeutics Ltd ADR (NQ: ANCN)
1.480   +0.010 (+0.68%)
Official Closing Price  /  Updated: 4:00 PM EST, Jan 23, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 19,000
Open 1.460
Bid (Size) 1.310 (20)
Ask (Size) 1.750 (8)
Prev. Close 1.470
Today's Range 1.452 - 1.490
52wk Range 1.040 - 11.50
Shares Outstanding N/A
Dividend Yield N/A
Performance
YTD
-4.96%
-4.96%
1 Month
+6.77%
+6.77%
3 Month
-31.16%
-31.16%
6 Month
-58.89%
-58.89%
1 Year
-86.30%
-86.30%
Top News
More News
Anchiano Therapeutics Announces Record Date for 2020 Annual General Meeting of Shareholders
from GlobeNewswire News Releases
Anchiano Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
from GlobeNewswire News Releases
More News
Read More
Anchiano Discontinues Phase 2 Codex Study Evaluating Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC); Company Focuses on Advancing Pan-RAS Inhibitor Program
from GlobeNewswire News Releases
Anchiano Therapeutics Chairman Stephen Hoffman Steps Down from Board
from GlobeNewswire News Releases
Anchiano Therapeutics Enters into An Exclusive Option To License Agreement for Novel Pan-RAS Inhibitor and PDE10/β-catenin Inhibitor Programs
from GlobeNewswire News Releases
Anchiano Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
from GlobeNewswire News Releases
Anchiano Therapeutics to Present at the Baird 2019 Global Healthcare Conference
from GlobeNewswire News Releases
Anchiano Therapeutics Reports Second Quarter 2019 Financial Results
from GlobeNewswire News Releases
Mid-Morning Market Update: Markets Open Higher; JC Penney Reports Narrower-Than-Expected Q3 Loss
category ANCN , RDNT , Eurozone , and 15 more.
from Benzinga
The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe
category XERS , SNGX , BVXV , and 40 more.
from Benzinga
The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon
category KPTI , XTLB , AFMD , and 79 more.
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.